http://www.fresenius.com en-us Mon, 05 Aug 2019 00:00:00 +0200 Mon, 05 Aug 2019 00:00:00 +0200 Mon, 05 Aug 2019 08:00:00 +0100 <![CDATA[Fresenius Helios expands preventive medicine offering]]> Fresenius Helios has opened a new Helios Prevention Center in Berlin, as the company continues the expansion of its occupational medicine activities into a standalone business area. The modern, 440-square-meter (4,700-square-foot) center in the heart of Germany’s capital offers comprehensive check-ups from a single source. HCP patients are accompanied throughout the check-up by their own personal physician, and do not have to search for the right department for their next test, deal with different contact persons, or face long waiting times. And if a test turns up something requiring medical treatment, the patient has direct access to the Helios healthcare network and an exclusive hotline for making appointments with specialists.

]]>
Tue, 30 Jul 2019 08:00:00 +0100 <![CDATA[Fresenius raises Group sales growth guidance after good second quarter]]> Stephan Sturm, CEO of Fresenius, said: “We are reporting a good second quarter 2019, with healthy organic growth in all four business segments. Our investments in future growth are moving ahead according to plan, as we further strengthen the foundations for the long-term, successful development of Fresenius. So we are very confident about the second half and the coming years.”

]]>
Tue, 30 Jul 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care on track to achieve full-year targets after solid second quarter]]> Rice Powell, CEO of Fresenius Medical Care, said: “We have delivered a solid second quarter with continued strong organic revenue growth. Net income in our underlying dialysis business developed in line with our expectations. We are confident to accelerate earnings growth over the second half of the year toward achieving our full-year targets. Due to ongoing delays in reconciliation of generated savings in the value-based ESCO pilot program and differing views with regard to the measurement mechanisms, it is prudent to adjust the rate of savings we applied to accrue revenues and earnings.

 

]]>
Fri, 19 Jul 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care celebrates 40th anniversary of Schweinfurt plant, company’s largest for dialysis machines]]> Fresenius Medical Care celebrated today the 40th anniversary of the company’s Schweinfurt, Germany plant. Joining employees and their family members for the festivities were numerous business and political representatives, including Schweinfurt Mayor Sebastian Remelé.

]]>
Wed, 10 Jul 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care sees U.S. plans for changes to kidney disease care as positive reinforcement of company’s strategy]]> Fresenius Medical Care is pleased the U.S. administration’s plans for changing the way care is provided to people with kidney disease supports its existing strategy. The company has long worked on various initiatives to promote home dialysis, improve access to transplants, and develop new, value-based care models for chronic kidney disease patients.

]]>
Tue, 09 Jul 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care North America invests in innovative medical wearable venture]]> Fresenius Medical Care North America (FMCNA) has announced an investment in BioIntelliSense, a Denver-based company that is developing a medical grade data services platform for continuous remote health monitoring, predictive analytics and algorithmic clinical insights. FMCNA is committed to bringing its expertise in advanced analytics and artificial intelligence to the development and deployment of this system in cooperation with BioIntelliSense. The aim is to jointly create clinical pathways that can alert clinicians to the need for early intervention, potentially preventing patients from complications and, thus, reducing unnecessary as well as costly hospitalizations. The investment, therefore, supports Fresenius Medical Care’s strategic goal to improve monitoring, interventions and outcomes for patients living with kidney disease and other chronic illnesses in order to increase their quality of life.

]]>
Wed, 03 Jul 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care expands clinical research activities]]> Fresenius Medical Care is expanding its clinical research activities. Frenova Renal Research (Frenova), previously a Fresenius Medical Care North America subsidiary, will now offer its services worldwide and will be integrated into the new Global Medical Office headed by Dr. Frank Maddux, Chief Medical Officer.

]]>
Fri, 14 Jun 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care successfully places USD bonds]]> Fresenius Medical Care yesterday successfully placed bonds with an aggregate principal amount of USD 500 million.

]]>
Thu, 06 Jun 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care organizes Organ Donation Day ]]> "Give life a chance" was the motto under which Fresenius Medical Care informed employees in Bad Homburg yesterday about organ donation. Individuals not only need to be well informed and carefully consider whether or not they wish to make an organ donation: Above all, they need to make a decision. 

]]>
Thu, 23 May 2019 08:00:00 +0100 <![CDATA[S&P upgrades Fresenius Medical Care to BBB with stable outlook]]> Standard & Poor’s has upgraded Fresenius Medical Care’s corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook.

]]>
Thu, 23 May 2019 08:00:00 +0100 <![CDATA[S&P upgrades Fresenius to BBB with stable outlook]]> Standard & Poor’s has revised Fresenius’ corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook. Fresenius is rated investment grade by the three leading rating agencies Standard & Poor’s (BBB/stable), Moody's (Baa3/stable) and Fitch (BBB-/stable).

]]>
Fri, 17 May 2019 08:00:00 +0100 <![CDATA[Annual General Meeting: Fresenius on course for continued growth, 26th straight increase in dividend approved]]> Fresenius remains on course for growth despite some recent challenges, Stephan Sturm, CEO of Fresenius, told the Annual General Meeting in Frankfurt today. “2018 was not an easy year, and yet it was a successful one,” he said in a speech to shareholders.

]]>
Thu, 16 May 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care stays on course for growth – Annual General Meeting approves 22nd straight dividend increase]]> Fresenius Medical Care is investing in further growth. At the Annual General Meeting in Frankfurt today, CEO Rice Powell explained the company's growth strategy: “We will be investing to the benefit of our patients – in innovation, efficiency and areas of growth. [...]"

]]>
Fri, 03 May 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches biosimilar adalimumab IDACIO® in Germany]]> Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.

]]>
Thu, 02 May 2019 08:00:00 +0100 <![CDATA[Fresenius makes solid start to 2019 and confirms Group guidance]]> Stephan Sturm, CEO of Fresenius, said: “We have made a successful start into 2019. All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year. (...)"

]]>
Thu, 02 May 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care with a good start into 2019]]> “In the first quarter we achieved healthy organic growth across all regions,” said Rice Powell, Chief Executive Officer of Fresenius Medical Care. “All of our major initiatives are underway."

]]>
Wed, 03 Apr 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO®]]> The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

]]>
Fri, 29 Mar 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care resolves FCPA investigation]]> Fresenius Medical Care announced today that it has entered into a Non-Prosecution Agreement with the U.S. Department of Justice and a separate agreement with the Securities and Exchange Commission to resolve matters governed by the U.S. Foreign Corrupt Practices Act (FCPA).

]]>
Wed, 20 Mar 2019 08:00:00 +0100 <![CDATA[Fresenius Medical Care appoints Dr. Frank Maddux as Global Chief Medical Officer]]> With this newly created position the company further advances the great importance of applying clinical science at an ever-higher level.

]]>
Tue, 19 Mar 2019 08:00:00 +0100 <![CDATA[Fresenius Helios and Marburger Bund agree on collective labor agreement]]> Helios Germany and the doctors' union Marburger Bund have agreed on a collective labor agreement for about 5,400 physicians in 34 Helios hospitals. It applies to the hospitals included in the Helios Group collective labor agreement. With effect from 1 January 2019, the base salary will increase by 2.5 percent. A further increase of 2.5 percent will follow on January 1, 2020. Salaries will thus increase by a total of 5 percent. This is in line with Fresenius Group's expectations.

]]>